Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply

Documents similaires

• Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
  par: Kaleb Tesfai, et autres
  Publié: (2025)
• Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
  par: Kelly Torosian, et autres
  Publié: (2025)
• Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
  par: Lana Bridi, et autres
  Publié: (2024)
• Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
  par: Shinya Yokoyama, et autres
  Publié: (2025)
• Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
  par: C. C. Mark Cheah, et autres
  Publié: (2025)